Lappoxo

Omeprazole, the active ingredient in Lappoxo, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders such as GERD and peptic ulcer disease.

GNH USA supplies Lappoxo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that addresses conditions caused by excess gastric acid.

- Gastroesophageal reflux disease (GERD): provides symptomatic relief by decreasing acid reflux and promoting healing of esophageal irritation. - Peptic ulcer disease: promotes ulcer healing by suppressing gastric acid production. - Helicobacter pylori eradication: enhances the effectiveness of antibiotic regimens used to eradicate the bacteria. - Erosive esophagitis: reduces inflammation and facilitates mucosal recovery by lowering acid exposure.

Omeprazole may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema) - Clostridioides difficile‑associated colitis - Hypomagnesemia (low magnesium levels) - Elevated liver enzymes - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Increased risk of bone fractures with long‑term use

When prescribing or dispensing Lappoxo, consider the following precautions to ensure safe use.

- Assess renal function: use with caution in patients with severe renal impairment. - Evaluate hepatic function: adjust or monitor use in patients with significant liver disease. - Monitor long‑term therapy: prolonged use may lead to vitamin B12 deficiency and bone density loss. - Review concomitant medications: potential for reduced efficacy of antiplatelet agents such as clopidogrel. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several medicines; appropriate management is required.

Major Interactions (Avoid): - Atazanavir: reduced absorption and therapeutic failure. - Ketoconazole: decreased antifungal efficacy. - Clopidogrel: diminished antiplatelet effect. - HIV protease inhibitors (e.g., ritonavir): altered plasma concentrations. - Warfarin: unpredictable changes in INR.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels. - Methotrexate: reduced renal clearance leading to toxicity. - Iron salts: decreased iron absorption. - Calcium carbonate: reduced omeprazole absorption. - Rifampin: decreased omeprazole plasma concentrations.